Loading...
•
Dec 31, 2023
Precigen Q4 2023 Earnings Report
Precigen reported full year financial results and provided business updates.
Key Takeaways
Precigen reported its full year 2023 financial results, with key highlights including progress in its AdenoVerse and UltraCAR-T programs. The company anticipates a transformative year in 2024, with pivotal Phase 2 data expected in Q2 and a BLA submission for PRGN-2012 in the second half of the year. A $10.4 million impairment charge was recorded in Q4 related to Exemplar subsidiary.
Anticipates presenting pivotal Phase 2 data in the second quarter and submitting a BLA for PRGN-2012 in the second half of 2024.
Preparing manufacturing facility and commercial operations in anticipation of the launch of PRGN-2012 in 2025.
Exciting updates expected from UltraCAR-T programs, which have garnered significant interest from potential partners.
Evaluating various financing opportunities to strengthen the balance sheet in preparation for the potential commercial launch of PRGN-2012 in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...